Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity
Chemical Biology & Drug Design · 2026
DOI: 10.1111/cbdd.70251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Tzu-Yu Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan. Hauptthemen laut MEDLINE: Aromatase Inhibitors, Estrone, Triple Negative Breast Neoplasms, Antineoplastic Agents. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Science and Technology Council.
Abstract (Originalsprache)
Aromatase inhibitors (AIs) are vital in the treatment of estrogen‐dependent breast cancer, especially in postmenopausal women. In this study, a series of steroidal glycosides (SGs) derived from trans ‐androsterone ( t AND), estrone (E1), and estradiol (E2) were synthesized using a one‐pot multi‐enzyme glycosylation approach and structurally characterized via HPLC, MS, and NMR. Among the synthesized compounds, E1‐α‐2DG ( 2b ) and E2‐α‐2DG ( 3b ) demonstrated the most potent aromatase inhibition, with IC 50 values of 0.101 ± 0.001 μM and 0.159 ± 0.009 μM, respectively. Molecular docking revealed that these glycosides form key hydrogen bonds with catalytic residues and the heme group of CYP19A1. In vitro cytotoxicity showed that E1‐α‐2DG selectively inhibited the growth of MCF‐7 and MDA‐MB‐231 breast cancer cells in a dose‐dependent manner, with the highest potency observed against triple‐negative MDA‐MB‐231 cells (IC 50 = 20.46 ± 2.92 μM), while exhibiting no toxicity toward non‐cancerous HEK293 cells. These findings suggest that glycosylation enhances the pharmacological potential of steroidal scaffolds and highlights E1‐α‐2DG as a promising lead compound for the development of safer, dual‐function breast cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsin-Chu, Taiwan.
- Center for Emergent Functional Matter Science, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
- Center for Intelligent Drug Systems and Smart Bio-Devices (IDS2B), National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
ORCID-Profile: Tung-Kung Wu
Förderung
- Ministry of Science and Technology, Taiwan
- National Science and Technology Council
Zitieren
APA
Huang, T. Y., Wang, M. R., Chou, F. P., Huang, S. C., Hsiao, P. Y., & Wu, T. K. (2026). Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70251
Vancouver
Huang TY, Wang MR, Chou FP, Huang SC, Hsiao PY, Wu TK. Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70251
BibTeX
@article{Huang2026,
author = {Huang, Tzu-Yu and Wang, Meng-Ru and Chou, Feng-Pai and Huang, Sheng-Cih and Hsiao, Po-Yun and Wu, Tung-Kung},
title = {Estrone‐α‐2‐Deoxy‐Glucoside as a Targeted Therapy for Triple‐Negative Breast Cancer: Aromatase Inhibition and Cytotoxicity},
journal = {Chemical Biology & Drug Design},
year = {2026},
doi = {10.1111/cbdd.70251}
}
EUVIMED